BioInfra Life Science바이오인프라생명과학
266470 · KONEX · ₩266470 · 바이오인프라생명과학
- Market cap
- ₩2.8B
- Enterprise value
- —
- P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- ROE
- —
- Net margin
- —
Financial statements not available yet. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−72.1% from the high
₩79Today: ₩88 – ₩99₩355
Returns
- 1W0.0%
- 1M−5.7%
- 3M0.0%
- 6M−4.8%
- YTD−64.0%
- 1Y−69.6%
- Volume today
- 1,833
- 0.3× the 20-day average
- Traded today
- ₩180,195
- Listed shares
- 27,866,019
- EPS (12 months)
- —
🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 31 of 100 (50 is a normal day for this stock).
- MomentumFlat-1% over the last month; the price is above its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
BioInfra Life Science stock overview
BioInfra Life Science (바이오인프라생명과학, KRX: 266470) is listed on KONEX, in the Biotech & Pharma sector. BioInfra Life Science develops blood-based multi-marker tests for early detection of high-risk groups for cancers such as breast, colorectal and ovarian cancer, and provides diagnostic testing services through a diagnostic testing hospital network. Its shares closed at ₩99 on Oct 28, 2026, up 4.21% on the day, giving it a market value of ₩2.8B.
Key facts
- Market cap
- ₩2.8B
- Sector
- Biotech & Pharma
- Latest price change
- +4.21%
- As of
- Oct 28, 2026
- Main business
- BioInfra Life Science develops blood-based multi-marker tests for early detection of high-risk groups for cancers such as breast, colorectal and ovarian cancer, and provides diagnostic testing services through a diagnostic testing hospital network.
Quick answers about BioInfra Life Science
- What does BioInfra Life Science do?
- BioInfra Life Science develops blood-based multi-marker tests for early detection of high-risk groups for cancers such as breast, colorectal and ovarian cancer, and provides diagnostic testing services through a diagnostic testing hospital network. The company also develops gene-based anticancer therapies and a targeted drug delivery platform using ultrasound and microbubbles, with cosmetic and functional skin-delivery products sold domestically and abroad. Its diagnostic services are offered mainly in Korea and to overseas partners in countries such as the United States, Kazakhstan and Singapore.
- What is the market cap of BioInfra Life Science?
- The market capitalisation of BioInfra Life Science was ₩2.8B at the close on Oct 28, 2026.
- Who are the largest shareholders of BioInfra Life Science?
- According to the latest official filings, the largest reported holders are Lee Jeong-ho (28.33%, as of Oct 22, 2024); Fancy Squad (11.41%, as of Dec 12, 2024); Blanc Tofu (10.69%, as of Dec 16, 2024).
- When is the next earnings report from BioInfra Life Science?
- Korean companies rarely announce results dates in advance. Based on when BioInfra Life Science filed the same report in past years, its next annual results is expected between Mar 20, 2027 and Mar 23, 2027.
Company profile
BioInfra Life Science develops blood-based multi-marker tests for early detection of high-risk groups for cancers such as breast, colorectal and ovarian cancer, and provides diagnostic testing services through a diagnostic testing hospital network. The company also develops gene-based anticancer therapies and a targeted drug delivery platform using ultrasound and microbubbles, with cosmetic and functional skin-delivery products sold domestically and abroad. Its diagnostic services are offered mainly in Korea and to overseas partners in countries such as the United States, Kazakhstan and Singapore.
Written by AI from the company's latest annual report.
- Korean name
- 바이오인프라생명과학
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 김승준
- Founded
- Jan 2001
- Listed
- Jul 2020
- Listed shares
- 27,866,019
- Fiscal year ends
- Month 12
- Website
- bioinfra.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent filings
See all- Change of Head Office LocationJul 30, 2026
- Results of Extraordinary Shareholders' MeetingJul 30, 2026
- Notice of shareholders' meetingJul 14, 2026
- Amended: Shareholders' meeting calledJun 18, 2026
- Shareholders' meeting calledJun 16, 2026
Titles in Korean until English translations are added.
Also known as: BioInfra Life Science / 바이오인프라생명과학 / 266470 / KRX:266470
Source: KRX statistical information